Alex received his PhD in biophysical chemistry from the University in Frankfurt/ Main, Germany. He was a Postdoc at the Harvard Medical School in Boston, MA, and an Oppenheimer Fellow at the Los Alamos National Laboratory (LANL) in Los Alamos, NM.
While working as a scientist at LANL, Alex developed two compounds to create a better vaccine for Tuberculosis (TB). In 2015, he took an entrepreneurial leave of absence from LANL to start Nature’s Toolbox, Inc. (NTx). Alex’s objective was to develop and commercialize a TB treatment based on two antibiotic compounds he created during his time in Los Alamos. In 2018 alone, a total of 1.5 million people died from TB. According to the World Health Organization, TB is the leading infectious disease resulting in death worldwide. Approximately one-quarter of the world’s population is infected with mycobacterium tuberculosis, the bacteria that causes TB.
Following NTx’s $47.5M Series B financing raise and a more than an eight-year sprint inventing and advancing NTx technologies, Alex decided to take time to recharge and refresh in early 2024, effectively stepping down from his hands-on role at Nature’s Toolbox.